Aspreva begins phase III trial in rare neuromuscular disease
1st Dec 2005, 02:24 GMT
Aspreva Pharmaceuticals, an emerging pharmaceutical company focused on treatments for less common diseases, has completed enrolment of 176 patients with myasthenia gravis in a phase III clinical study evaluating its drug, MMF.
Aspreva begins phase III trial in rare neuromuscular disease related news:
- Aspreva Announces Completion of Patient Enrolment in Phase III Clinical Trial for CellCept in Myasthenia Gravis — PR Newswire: All Releases
- Positive phase III trial for InSite eye antibiotic — Pharmaceutical Business Review Online
- Provectus Begins Phase 1 Breast Cancer Trial — Surgery News from StratCenter.com
- BiovaxID Vaccine Therapy Of Follicular Lymphoma In First Remission, Ongoing Phase III Trial Update — Medical News Today RSS/XML Feed
- GlaxoSmithKline sieht 7 Medikamente kurzfristig in Phase III — Finanztreff.de / BRANCHEN
- Axonyx Reports Statistically Significant Result for Phenserine in Alzheimer's Disease — StratWire - Business of Healthcare NewsFeed
- Tibotec Discontinues Exploratory Trial With TMC125 — Pharmaceuticals News from StratCenter.com
- Inhibitex Announces Favorable Regulatory Developments for Veronate — Pharmaceuticals News from StratCenter.com
- Sangamo BioSciences Completes Enrollment and Treatment in Phase 1 Clinical Trial of ZFP Therapeutic in Diabetic Neuropathy — Nephrology/ Dialysis News from StratCenter.com
- Penalty phase of Camacho trial begins — SignOnSanDiego.com: Local News
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol